Impact of Metformin and Rosiglitazone Treatment on Glucose Transporter 4 mRNA Expression in Women with Polycystic Ovary Syndrome
April 2008
in “
European journal of endocrinology
”
New to Metformin? There is a guide in the encyclopedia. Read the guide → 
Studysummary In this study, treatment with insulin sensitizers significantly increased adipose tissue GLUT4 mRNA expression and improved insulin resistance, menstrual patterns, and androgen profiles in PCOS patients, with rosiglitazone being more effective than metformin. Our plain-language summary of this paper — not a Tressless recommendation.
The study from 2008 examined the impact of metformin and rosiglitazone on glucose transporter 4 (GLUT4) mRNA expression in 35 women with polycystic ovary syndrome (PCOS), with 33 completing the trial. After 6 months of treatment, both drugs significantly increased GLUT4 mRNA expression in adipose tissue, with rosiglitazone showing a more pronounced effect. Improvements were also seen in insulin resistance, as indicated by the Homeostasis Model Assessment (HOMAIR) score, menstrual bleeding frequency, and serum total testosterone levels. The study concluded that both metformin and rosiglitazone enhance clinical, hormonal, and metabolic parameters in PCOS patients, with neither drug proving superior. Further research was suggested to explore the mechanisms of these treatments and their efficacy in different patient subgroups.
